FAQs
The average price target for Outlook Therapeutics is $35.00. This is based on 4 Wall Streets Analysts 12-month price targets, issued in the past 3 months. The highest analyst price target is $50.00 ,the lowest forecast is $25.00.
What is the target for Outlook Therapeutics stock? ›
Stock Price Target OTLK
| High | $53.00 |
|---|
| Median | $35.00 |
| Low | $25.00 |
| Average | $37.43 |
| Current Price | $7.67 |
The consensus rating for Outlook Therapeutics stock is Moderate Buy based on the current 1 hold rating and 7 buy ratings for OTLK.
What is the stock forecast for Otlk in 2030? ›
Outlook Therapeutics stock prediction for 1 year from now: $ 39.56 (412.42%) Outlook Therapeutics stock forecast for 2025: $ 8.17 (8.11%) Outlook Therapeutics stock prediction for 2030: $ 12.07 (59.64%)
What is target price outlook? ›
TGT Stock 12 Month Forecast
Based on 28 Wall Street analysts offering 12 month price targets for Target in the last 3 months. The average price target is $179.81 with a high forecast of $210.00 and a low forecast of $116.00.
What is the price target forecast? ›
A price target is a price at which an analyst believes a stock to be fairly valued relative to its projected and historical earnings. When an analyst raises their price target for a stock, they generally expect the stock price to rise.
Who are the competitors of Outlook Therapeutics? ›
Competitor comparison
- Coherus BioSciences Inc Headquarters. 306. $257.2M.
- EyePoint Pharmaceuticals Inc Headquarters. 121. $46.0M.
- MeiraGTx Holdings Plc Headquarters. 402. $14.0M.
- Eyenovia Inc Headquarters. $3,800.
VTGN Stock 12 Month Forecast
Based on 1 Wall Street analysts offering 12 month price targets for VistaGen Therapeutics in the last 3 months. The average price target is $12.00 with a high forecast of $12.00 and a low forecast of $12.00. The average price target represents a 216.62% change from the last price of $3.79.
What does Outlook Therapeutics do? ›
It develops, manufactures and commercializes biosimilar products in the areas of ophthalmology.
What is the best medical stock to buy right now? ›
Comparison Results
| Name | Price | Analyst Consensus |
|---|
| LLY Eli Lilly & Co | $885.01 | 16 Buy 3 Hold 0 Sell Strong Buy |
| CVS CVS Health | $61.09 | 10 Buy 9 Hold 0 Sell Moderate Buy |
| UNH UnitedHealth | $489.23 | 18 Buy 2 Hold 0 Sell Strong Buy |
| TDOC Teladoc | $10.11 | 5 Buy 14 Hold 0 Sell Moderate Buy |
5 more rowsOn average, analysts forecast that OTLK's EPS will be -$4.02 for 2024, with the lowest EPS forecast at -$4.26, and the highest EPS forecast at -$3.77. On average, analysts forecast that OTLK's EPS will be -$2.45 for 2025, with the lowest EPS forecast at -$3.22, and the highest EPS forecast at -$2.05.
Who owns Outlook Therapeutics Institutional? ›
Largest shareholders include Tang Capital Management Llc, Great Point Partners Llc, Armistice Capital, Llc, Sphera Funds Management Ltd., BlackRock Inc., Velan Capital Investment Management LP, Caligan Partners LP, Vanguard Group Inc, Schonfeld Strategic Advisors LLC, and IWM - iShares Russell 2000 ETF .
What is the rating of Outlook Therapeutics? ›
Outlook Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.88, and is based on 7 buy ratings, 1 hold rating, and no sell ratings.
Which stock will go up in 2030? ›
Target 2030
| S.No. | Name | CMP Rs. |
|---|
| 1. | Electrost.Cast. | 165.59 |
| 2. | Navneet Educat. | 152.03 |
| 3. | O N G C | 271.55 |
| 4. | Innova Captab | 496.35 |
17 more rowsTarget is forecast to grow earnings and revenue by 6.4% and 3.1% per annum respectively. EPS is expected to grow by 7.6% per annum. Return on equity is forecast to be 27.8% in 3 years.
What is the price prediction for ABBV? ›
Based on analyst ratings, AbbVie's 12-month average price target is $185.79. AbbVie has 8.42% upside potential, based on the analysts' average price target. AbbVie has a consensus rating of Strong Buy which is based on 13 buy ratings, 3 hold ratings and 0 sell ratings. The average price target for AbbVie is $185.79.
What is the stock price forecast for Poai in 2030? ›
According to our Predictive Oncology stock prediction for 2030, POAI stock will be priced at $ 69.65M in 2030. This forecast is based on the stock's average growth over the past 10 years.
